| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1032059331 |
| P356 | DOI | 10.1038/NRD4308 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd4308 |
| P932 | PMC publication ID | 4208620 |
| P698 | PubMed publication ID | 25176435 |
| P5875 | ResearchGate publication ID | 265212165 |
| P50 | author | Jens Meiler | Q29315318 |
| Colleen M. Niswender | Q67215380 | ||
| Craig W. Lindsley | Q67215429 | ||
| P. Jeffrey Conn | Q67215432 | ||
| P2860 | cites work | The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization | Q24293767 |
| Activation and allosteric modulation of a muscarinic acetylcholine receptor | Q24308061 | ||
| Structure of class B GPCR corticotropin-releasing factor receptor 1 | Q24309523 | ||
| Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator | Q24338769 | ||
| Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR | Q24556662 | ||
| Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex | Q24602550 | ||
| Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM) | Q24625985 | ||
| Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS | Q24629746 | ||
| Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 | Q24645178 | ||
| Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells | Q24646463 | ||
| Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. | Q24647634 | ||
| Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia | Q24649568 | ||
| Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats | Q24652668 | ||
| Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment | Q24655595 | ||
| A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning | Q24657785 | ||
| Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity | Q24657902 | ||
| The concept of allosteric interaction and its consequences for the chemistry of the brain | Q26827321 | ||
| Drugs for allosteric sites on receptors | Q27006721 | ||
| Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor | Q27646733 | ||
| Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain | Q27694576 | ||
| Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer | Q28213709 | ||
| Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins | Q28244789 | ||
| Allosteric modulation of the cannabinoid CB1 receptor | Q28268355 | ||
| How many drug targets are there? | Q28276660 | ||
| CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding | Q28370513 | ||
| 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist | Q28374719 | ||
| SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5 | Q28378193 | ||
| Assessment and challenges of ligand docking into comparative models of G-protein coupled receptors | Q28534461 | ||
| Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease | Q28660933 | ||
| Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study | Q45249900 | ||
| Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons | Q46370920 | ||
| G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor | Q46421423 | ||
| Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. | Q46471412 | ||
| Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation | Q46779820 | ||
| Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration | Q48329195 | ||
| Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. | Q48436289 | ||
| Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. | Q50470980 | ||
| The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. | Q50790850 | ||
| Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. | Q50952521 | ||
| Allosteric Modulation of G Protein–Coupled Receptors | Q56115675 | ||
| Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands | Q57838214 | ||
| Overview of Receptor Allosterism | Q60299786 | ||
| Metabotropic glutamate receptor 5 is a disulfide-linked dimer | Q71763241 | ||
| Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. | Q37784750 | ||
| Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives | Q37828013 | ||
| Dimers and beyond: The functional puzzles of class C GPCRs. | Q37831552 | ||
| mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents | Q37831917 | ||
| "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology | Q37845809 | ||
| Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development | Q37896837 | ||
| Allostery in GPCRs: 'MWC' revisited. | Q37932797 | ||
| Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature | Q38002888 | ||
| Role of metabotropic glutamate receptors in persistent forms of hippocampal plasticity and learning | Q38022385 | ||
| Emerging opportunities for allosteric modulation of G-protein coupled receptors | Q38043240 | ||
| Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. | Q38070176 | ||
| mGlu5 negative allosteric modulators: a patent review (2010-2012). | Q38075897 | ||
| Signalling bias in new drug discovery: detection, quantification and therapeutic impact. | Q38081692 | ||
| Emerging paradigms in GPCR allostery: implications for drug discovery | Q38125563 | ||
| A unique industrial-academic collaboration towards the next generation of schizophrenia therapeutics | Q38166857 | ||
| Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators | Q38649976 | ||
| Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines | Q38687186 | ||
| Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode | Q39222571 | ||
| Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. | Q39314038 | ||
| Functional importance of GLP-1 receptor species and expression levels in cell lines. | Q39411043 | ||
| Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. | Q39419158 | ||
| A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. | Q39657918 | ||
| Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization | Q39942670 | ||
| A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. | Q39947679 | ||
| A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties | Q40157034 | ||
| Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. | Q40170457 | ||
| Cyclic AMP-dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to phospholipase D stimulation | Q40271340 | ||
| A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators | Q40374968 | ||
| Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells | Q41059064 | ||
| Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia? | Q41790775 | ||
| Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and implications for antiepileptic drug design | Q42139378 | ||
| Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes | Q42483396 | ||
| Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. | Q42710710 | ||
| Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target | Q42713510 | ||
| A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease | Q42717015 | ||
| Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia | Q42719140 | ||
| Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects | Q42726130 | ||
| Discovery of an ectopic activation site on the M(1) muscarinic receptor | Q42815075 | ||
| Potentiating mGluR5 function with a positive allosteric modulator enhances adaptive learning | Q43082537 | ||
| Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist | Q43292922 | ||
| Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. | Q43657512 | ||
| Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum | Q43658177 | ||
| Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor | Q44267726 | ||
| The mGluR theory of fragile X mental retardation | Q29615060 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Structural diversity of G protein-coupled receptors and significance for drug discovery | Q29616716 | ||
| A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors | Q30406728 | ||
| Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100 | Q30410518 | ||
| N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement. | Q30427199 | ||
| Allosteric modulation of metabotropic glutamate receptors | Q30448534 | ||
| The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. | Q30458705 | ||
| Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity | Q30472643 | ||
| Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system | Q30474039 | ||
| Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation | Q30489795 | ||
| Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5 | Q30498430 | ||
| Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties | Q30498538 | ||
| Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity | Q30535764 | ||
| Structure-function of the G protein-coupled receptor superfamily | Q30576993 | ||
| Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. | Q33268568 | ||
| An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission | Q33308569 | ||
| Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold | Q33343388 | ||
| Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M(1) positive allosteric modulators | Q33518104 | ||
| Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7 | Q33520184 | ||
| Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators | Q33755292 | ||
| mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning | Q33908562 | ||
| Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm | Q34021713 | ||
| The angiotensin II AT2 receptor is an AT1 receptor antagonist. | Q34086986 | ||
| A new benzodiazepine pharmacology. | Q34106026 | ||
| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
| A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. | Q34222874 | ||
| Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. | Q34278605 | ||
| Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain | Q34314050 | ||
| ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization | Q34318862 | ||
| Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers | Q34334835 | ||
| Development of allosteric modulators of GPCRs for treatment of CNS disorders | Q34373958 | ||
| A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators | Q34518807 | ||
| G protein-coupled receptor allosterism and complexing | Q34523552 | ||
| Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors | Q34608007 | ||
| Exploring a role for heteromerization in GPCR signalling specificity | Q34660378 | ||
| Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. | Q34672123 | ||
| ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti | Q34815750 | ||
| The use of constitutively active GPCRs in drug discovery and functional genomics | Q34981350 | ||
| Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. | Q35688485 | ||
| Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator | Q35760205 | ||
| Allosteric modulators: the new generation of receptor antagonist | Q35860365 | ||
| Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation | Q35874442 | ||
| Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery | Q35952381 | ||
| Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models | Q36099440 | ||
| Functional and pharmacological characteristics of metabotropic glutamate receptors 2/4 heterodimers | Q36174739 | ||
| Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships | Q36335613 | ||
| A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling | Q36717066 | ||
| Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology | Q36776760 | ||
| Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. | Q36880915 | ||
| The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization | Q36935273 | ||
| Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. | Q36959071 | ||
| Calcium sensing receptor activators: calcimimetics | Q37066049 | ||
| N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity | Q37089832 | ||
| Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synapse. | Q37101834 | ||
| Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors | Q37199099 | ||
| Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks | Q37220392 | ||
| Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | Q37360436 | ||
| Allosteric modulators of GABA(B) receptors: mechanism of action and therapeutic perspective. | Q37420482 | ||
| The role of dimerisation in the cellular trafficking of G-protein-coupled receptors | Q37619942 | ||
| Metabotropic glutamate receptors: physiology, pharmacology, and disease | Q37670222 | ||
| G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives | Q37680849 | ||
| Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential | Q37773480 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | G protein-coupled receptor | Q38173 |
| P304 | page(s) | 692-708 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders | |
| P478 | volume | 13 |
| Q34243209 | 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites |
| Q52558952 | A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity. |
| Q47979078 | Activation processes in ligand-activated G protein-coupled receptors: A case study of the adenosine A2A receptor |
| Q35529175 | Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family |
| Q26747395 | Allosteric Modulation of Chemoattractant Receptors |
| Q39284158 | Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders |
| Q41560616 | Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review. |
| Q38614218 | Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer. |
| Q30843868 | Allosteric cross-talk in chromatin can mediate drug-drug synergy |
| Q57120289 | Allosteric modulation of the farnesoid X receptor by a small molecule |
| Q97595098 | Allosteric molecular switches in metabotropic glutamate receptors |
| Q47549341 | An Interaction between Serotonin Receptor Signaling and Dopamine Enhances Goal-Directed Vigor and Persistence in Mice |
| Q40973806 | Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand. |
| Q74441860 | Antidepressants at work |
| Q27305419 | Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents |
| Q90576739 | Challenges in the Discovery and Optimization of mGlu2/4 Heterodimer Positive Allosteric Modulators |
| Q38876214 | Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors. |
| Q30398567 | Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins. |
| Q37167965 | Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators |
| Q90403913 | Construction of a Fluorescent Screening System of Allosteric Modulators for the GABAA Receptor Using a Turn-On Probe |
| Q50872293 | Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. |
| Q89394623 | Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog |
| Q58693044 | Current Concepts and Treatments of Schizophrenia |
| Q98773154 | Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor |
| Q40435465 | Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type |
| Q38439440 | Development of Photoactivatable Allosteric Modulators for the Chemokine Receptor CXCR3. |
| Q28573244 | Developmental and adult expression patterns of the G-protein-coupled receptor GPR88 in the rat: Establishment of a dual nuclear-cytoplasmic localization |
| Q52653356 | Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators. |
| Q40994323 | Differential modulation of the lactisole 'Sweet Water Taste' by sweeteners |
| Q51039534 | Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter. |
| Q88424190 | Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold |
| Q38436762 | Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition |
| Q38437959 | Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core |
| Q42271745 | Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). |
| Q47887304 | Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2. |
| Q42145142 | Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy |
| Q36050350 | Discovery of Small-Molecule Modulators of the Human Y4 Receptor |
| Q41371056 | Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia |
| Q46417915 | Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia |
| Q39077987 | Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs |
| Q26739930 | Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences |
| Q64969552 | Does the lipid bilayer orchestrate access and binding of ligands to transmembrane orthosteric/allosteric sites of GPCRs? |
| Q47987383 | Effect of Novel Allosteric Modulators of Metabotropic Glutamate Receptors on Drug Self-administration and Relapse: A Review of Preclinical Studies and Their Clinical Implications |
| Q92949088 | Evaluation of Synthetic Cytochrome P450-Mimetic Metalloporphyrins To Facilitate "Biomimetic" Biotransformation of a Series of mGlu5 Allosteric Ligands |
| Q102372880 | Explicit Treatment of Non Michaelis-Menten and Atypical Kinetics in Early Drug Discovery |
| Q37740652 | From Engrams to Pathologies of the Brain |
| Q35671393 | From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. |
| Q26752403 | G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs |
| Q58568628 | GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures |
| Q36946647 | GPR171 expression enhances proliferation and metastasis of lung cancer cells |
| Q38878129 | Guidelines for the Synthesis of Small-Molecule Irreversible Probes Targeting G Protein-Coupled Receptors. |
| Q35972120 | Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator |
| Q90501515 | Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach |
| Q30666176 | Label noise in subtype discrimination of class C G protein-coupled receptors: A systematic approach to the analysis of classification errors |
| Q36098318 | Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes |
| Q90467603 | Lrrc7 mutant mice model developmental emotional dysregulation that can be alleviated by mGluR5 allosteric modulation |
| Q88786315 | Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies |
| Q39153205 | Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder |
| Q30619467 | Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction |
| Q39319839 | Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities |
| Q34468639 | Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation |
| Q26773431 | Neurobiological Insights from mGlu Receptor Allosteric Modulation |
| Q37140411 | New paradigms in GPCR drug discovery. |
| Q88337997 | Niclosamide is a Negative Allosteric Modulator of Group I Metabotropic Glutamate Receptors: Implications for Neuropathic Pain |
| Q38882060 | Nociception modulation by supraspinal group III metabotropic glutamate receptors |
| Q28081112 | Novel Allosteric Modulators of G Protein-coupled Receptors |
| Q39039972 | Novel PAMs Targeting NMDAR GluN2A Subunit |
| Q90679977 | Oligomeric Receptor Complexes and Their Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New Biological Principle for Integration of Signals in the CNS |
| Q27318675 | Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice |
| Q38698653 | Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells |
| Q48354605 | Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. |
| Q48001582 | Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia |
| Q37183072 | Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors |
| Q28078759 | Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction? |
| Q92431288 | Progress toward allosteric ligands of metabotropic glutamate 7 (mGlu7) receptor: 2008-present |
| Q89174583 | Reagent Validation to Facilitate Experimental Reproducibility |
| Q89948584 | Recent advances in dopaminergic strategies for the treatment of Parkinson's disease |
| Q38674558 | Recent developments in the behavioural and pharmacological enhancement of extinction of drug seeking |
| Q34907032 | Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles |
| Q64759887 | Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders |
| Q39057006 | Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report |
| Q97644040 | Structural Insight into the Mechanism of 4-Aminoquinolines Selectivity for the alpha2A-Adrenoceptor |
| Q64082112 | Structural insights into the differences among lactisole derivatives in inhibitory mechanisms against the human sweet taste receptor |
| Q91749643 | Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development |
| Q64760299 | The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum |
| Q38863882 | The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies |
| Q88653703 | The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core |
| Q30371933 | The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia |
| Q43180212 | Utilizing GCaMP transgenic mice to monitor endogenous Gq/11-coupled receptors |
| Q91789039 | VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events |
Search more.